MEDNAX Inc (NYSE:MD) insider John C. Pepia sold 6,516 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $46.56, for a total value of $303,384.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MEDNAX stock traded down $1.72 during midday trading on Thursday, reaching $44.86. 43,637 shares of the stock traded hands, compared to its average volume of 841,941. MEDNAX Inc has a 12-month low of $40.56 and a 12-month high of $63.04. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.74 and a quick ratio of 1.74.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Monday, April 30th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. The business had revenue of $901.90 million during the quarter, compared to analysts’ expectations of $903.75 million. MEDNAX had a return on equity of 10.13% and a net margin of 9.34%. The business’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 EPS. equities research analysts anticipate that MEDNAX Inc will post 3.94 earnings per share for the current year.

A number of brokerages recently issued reports on MD. TheStreet raised MEDNAX from a “c+” rating to a “b” rating in a research report on Monday, March 12th. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a research report on Saturday, May 5th. Jefferies Financial Group set a $58.00 target price on MEDNAX and gave the company a “hold” rating in a report on Thursday, March 15th. Credit Suisse Group lowered their target price on MEDNAX to $57.00 and set a “neutral” rating for the company in a report on Monday, May 7th. Finally, Citigroup lowered their target price on MEDNAX from $57.00 to $50.00 and set a “neutral” rating for the company in a report on Friday, May 4th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $55.92.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in MEDNAX by 1.8% during the first quarter. BlackRock Inc. now owns 7,879,949 shares of the company’s stock worth $438,360,000 after purchasing an additional 139,407 shares during the last quarter. Blue Harbour Group L.P. lifted its stake in MEDNAX by 9.7% during the first quarter. Blue Harbour Group L.P. now owns 4,508,868 shares of the company’s stock worth $250,828,000 after purchasing an additional 397,600 shares during the last quarter. Pzena Investment Management LLC lifted its stake in MEDNAX by 134.8% during the first quarter. Pzena Investment Management LLC now owns 2,258,712 shares of the company’s stock worth $125,652,000 after purchasing an additional 1,296,682 shares during the last quarter. Earnest Partners LLC increased its position in MEDNAX by 48.1% during the fourth quarter. Earnest Partners LLC now owns 2,212,691 shares of the company’s stock worth $118,246,000 after buying an additional 718,317 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in MEDNAX by 21.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,058,056 shares of the company’s stock worth $114,488,000 after buying an additional 365,955 shares during the period. Institutional investors and hedge funds own 97.39% of the company’s stock.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Insider Buying and Selling by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.